There exist opportunities to develop and refine tools that (1) address PSDM modes beyond weighing treatment options, (2) cover a wider variety of rheumatologic conditions, and (3) more transparently report evaluation of PDA content, development, and delivery.
Kumar et al. (Fri,) studied this question.